Prof. Dr. Christoph Mundhenke



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer (2011) Von Minckwitz G, Schweller K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, et al. Journal article In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells (2010) Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, et al. Journal article Therapeutic recommendations for mammary carcinoma Therapieempfehlungen bei mammakarzinom (2010) Mundhenke C Journal article Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer (2010) Bauerschlag DO, Habermann M, Weimer J, Meinhold-Heerlein I, Hilpert F, Weigel M, Bauer M, et al. Journal article Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) Witzel I, Loibl S, Von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, et al. Journal article Dexrazoxane (Savene) is the standard therapy for anthracycline extravasation Dexrazoxan (Savene) als Standard in der Therapie von Anthrazyklinparavasaten (2010) Mundhenke C Journal article Giant basal cell carcinoma of the breast mimicking Paget's disease: Complete remission after photodynamic therapy (2010) Mikhaimer NC, Kaehler KC, Schwarz T, Mundhenke C, Hauschild A Journal article Breast carcinoma - New aspects from practice and politics Mammakarzinom - Neue Aspekte aus Praxis und Politik (2010) Jonat W, Kreienberg R, Janni W, Mundhenke C Journal article Breast cancer therapies: Increasing costs in the age of targeted therapies. An unethical discussion? Mammakarzinomtherapie: Kostenentwicklung im zeitalter zielgerichteter therapien: Eine anstößige Diskussion? (2010) Mundhenke C, Schem C, Weigel M, Strauss A Journal article Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γσ T cells (2009) Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, et al. Journal article